Inventor · disambiguated record
Nicholas Morra
Also filed as: MORRA NICHOLAS
5 granted patents·6 pending applications·5 citations·filing 2015–2025
69Inventor score
Top patents by PatentIndex Score
11 records- 0188US11993577B2Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomersEMPATHBIO INC·Filed 2022·Granted May 28, 2024·2 cites·32 claims
- 0285US12378194B2N, n-dimethyltryptamine salts and crystalline salt formsATAI THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·2 cites·16 claims
- 0372US10407411B2Purified cenicriviroc and purified intermediates for making cenicrivirocTOBIRA THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·1 cites·16 claims
- 0471US12492178B2Stable polymorph of R-MDMA HClEMPATHBIO INC·Filed 2023·Granted Dec 9, 2025·0 cites·11 claims
- 0571US2025388538A1N,n-dimethyltryptamine salts and crystalline salt formsATAI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0663US2021171504A1Purified cenicriviroc and purified intermediates for making cenicrivirocTOBIRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0761US2024208920A1Synthesis of mda or its optically active (r)- or (s)-mda isomersEMPATHBIO INC·Filed 2023·Application pending·0 cites
- 0856US2020095229A1Purified cenicriviroc and purified intermediates for making cenicrivirocTOBIRA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0952US2020216476A1Process of making cenicriviroc and related analogsTOBIRA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1050US2023109467A1Preparation of optically active enantiomers of piperonyl amines by resolution of the diastereomeric saltsATAI Life Sciences AG·Filed 2022·Application pending·0 cites
- 1148US10526349B2Process of making cenicriviroc and related analogsTOBIRA THERAPEUTICS INC·Filed 2015·Granted Jan 7, 2020·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when Nicholas Morra files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →